• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

    10/20/21 8:30:00 AM ET
    $FLDM
    Biotechnology: Laboratory Analytical Instruments
    Capital Goods
    Get the next $FLDM alert in real time by email

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market.

    Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 8, 2021, to discuss third quarter 2021 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

    Individuals interested in listening to the conference call may do so by dialing:

    US domestic callers: (877) 556-5248

    Outside US callers: (720) 545-0029

    Please reference Conference ID: 5579013

    Live audio of the webcast will be available online from the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived on Fluidigm's Investor Relations page at investors.fluidigm.com and will be available until November 15.

    About Fluidigm

    Fluidigm (NASDAQ:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

    Fluidigm, and the Fluidigm logo are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners.

    Available Information

    We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

    Contact:

    Peter DeNardo 

    415 389 6400

    [email protected]



    Primary Logo

    Get the next $FLDM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FLDM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:11:15 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:06:21 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:05:59 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    SEC Filings

    See more

    $FLDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      7/7/22 4:00:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/27/22 4:04:35 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/16/22 2:06:26 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Piper Sandler reiterated coverage on Fluidigm with a new price target

      Piper Sandler reiterated coverage of Fluidigm with a rating of and set a new price target of $8.00 from $15.00 previously

      2/11/21 12:35:14 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Leadership Updates

    Live Leadership Updates

    See more
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

      Caligan Partners to Vote "FOR" Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney, a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeting SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a support agreement with Caligan Partners LP ("Caligan"), Fluidigm's current largest holder of common stock, under which Caligan has agreed to vote "FOR" all Fluidigm proposals related to the

      3/29/22 9:29:06 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem in South San Francisco and appointed Gajus Worthington to its Board of Directors. The Company is now positioned to accelerate the translation of its proprietary cf-mRNA Liquid Biopsy Technology Platform to develop products and services for Precision Medicine clinical practice and biopharma R&D. "We

      1/4/22 6:00:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      6/7/22 10:31:54 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      5/3/22 12:40:48 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13G filed by Fluidigm Corporation

      SC 13G - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      4/14/22 5:09:34 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Financials

    Live finance-specific insights

    See more
    • Fluidigm Announces Third Quarter 2021 Financial Results

      Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the third quarter ended September 30, 2021. "We saw a very active third quarter and made progress with our ambitious plan to commercially scale two new instrument systems," said Chris Linthwaite, President and CEO. "Core demand for our products was healthy, but we were unable to fulfill all orders for our products during the quarter, largely due to supply chain issues. Our b

      11/8/21 4:02:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

      SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 8, 2021, to discuss third quarter 2021 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals int

      10/20/21 8:30:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million

      Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the second quarter ended June 30, 2021. "Second quarter results were driven by a rebound in our base business and early customer orders following the launch of our new fourth generation CyTOF® XT mass cytometry product," said Chris Linthwaite, President and CEO. "Our services busines

      8/5/21 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (NASDAQ:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm, the Company's new President, Chief Executive Officer and a member of the Company's Board of Directors, and Hanjoon (Alex) Kim, the Company's new Chief Operating Officer, and a new employee, Ardalan (Alex) Arfaei, the Company's new Senior Vice President, Corporate Development. In accordance with Nasdaq Listing Rule 5635(c)(4), Standard BioTools' Compensation Committee of its Board of Directors, which is composed entirely

      4/5/22 7:15:24 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

      SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Dr. Carlos V. Paya, chairman of Fluidigm, said, "On behalf of the Board of Directors, I would like to thank our stockholders for their support of this investment, which is expected to fuel a realization of identified growth and cost opportunities within the Company's two major platforms, mass cytometry and microfluidics, and pave the way

      4/1/22 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods